Cognision, a provider of advanced neurobiomarker technology, on Friday announced a partnership with precision neuropsychiatry specialist Kynexis to use the COGNISION System in Kynexis' Phase 2 clinical trial of KYN-5356 in subjects with schizophrenia.
KYN-5356 is designed to inhibit KAT-II, an enzyme central to the kynurenine pathway implicated in cognitive impairment associated with schizophrenia (CIAS) -- a debilitating symptom for which no approved treatments currently exist. The ongoing Phase 2 study aims to establish proof of clinical concept for KYN-5356 by demonstrating its efficacy in improving cognitive performance.
Kynexis will use the COGNISION System to precisely measure drug-induced changes in brain function.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA